

1061 East Main Street, Suite 300, East Dundee, Illinois 60118 • (847) 752-5355 email: info@aacuweb.org • website: aacuweb.org

OFFICERS

President

Damara L. Kaplan, PhD, MD

Albuquerque, NM

President-Klect William C. Reha, MD, MBA Woodbridge, VA

Secretary/Treasurer Lisa I Finkelstein, DO Jackson, WY

Elliott R. Lieberman, MD Dix Hills, NY

Health Policy Chair Terrence C. Regan, MD Palm Coast, FL

State Advocacy Network Chair Harbhajan S. Ajrawat, MD Annapolis, MD

SECTION REPRESENTATIVES Mid-Albantic Jennifer U. Miles-Thomas, MD Virginia Beach, VA

New England Brian H. Irwin, MD Burlington, VT

New York
Amanda C. North, MD
Bronx, NY

North Central James A. Brown, MD Iowa City, IA

North eastern Mark D. White, MD, FACS Albany, NY

South Central James H. Gilbaugh III, MD, FACS Wichita, KS

South eastern Kevin K. Lee, MD, FACS Winter Haven, FL

Western Edward S. Cohen, MD, FACS San Diego, CA

EXECUTIVE OFFICE Roscutive Directur Jennifer Stevens

Annociate Director, Leginlative Affairn Kristin Jimison

Proponent Written Testimony to the Ohio House Health Committee House Bill 608 November 28, 2022

The American Association of Clinical Urologists (AACU) is a leading professional organization for the specialty of urology, a branch of medicine that focuses on conditions affecting the urinary-tract system and male reproductive organs. The AACU represents the interests of more than 500 urologists in Ohio and more than 3,000 nationwide. As many of our members provide care for patients with cancer, we appreciate the opportunity to express our support for HB 608, a bill that will help ensure more more Ohioans can benefit from biomarker testing—the key to unlocking targeted therapies.

Specifically, we support legislative action to ensure Ohioans covered by state-regulated insurance plans, including Medicaid, have coverage for biomarker testing when medically appropriate.

Advances in the laboratory increasingly provide clinicians with patient-specific genomic information that contributes to individualized risk-stratification, treatment planning, and assessment of hereditary cancer risk. Legislation to expand coverage of biomarker testing in Ohio would make it possible for more patients to get the right treatment at the right time, and we respectfully request that the members of the Ohio House of Representatives support biomarker testing legislation.

